Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.44 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2333789 | 0.96 | ALDH1A1 (0.51) | FKBP1AALDH1A1BCHEACHEHTT | |
| SCHEMBL6803332 | 0.91 | ALDH1A1 (0.55) | FKBP1AALDH1A1BCHEACHEHTT | |
| SCHEMBL2567795 | 0.91 | ALDH1A1 (0.47) | FKBP1AALDH1A1SMN1; SMN2PSMD10CNR2 | |
| SCHEMBL18934371 | 0.91 | ALDH1A1 (0.47) | FKBP1AALDH1A1SMN1; SMN2PSMD10CNR2 | |
| SCHEMBL13649253 | 0.89 | ENPP1 (0.52) | FKBP1AALDH1A1HTTSMN1; SMN2MAPT | |
| SCHEMBL890360 | 0.88 | PTGS2 (0.52) | FKBP1AALDH1A1BCHEACHEHTT | |
| SCHEMBL8710128 | 0.87 | ALDH1A1 (0.51) | FKBP1AALDH1A1BCHEACHEHTT | |
| SCHEMBL18926560 | 0.87 | GAA (0.50) | FKBP1AALDH1A1BCHEACHEHTT | |
| SCHEMBL20610741 | 0.86 | F2RL1 (0.51) | FKBP1AALDH1A1BCHEACHEHTT | |
| SCHEMBL18926554 | 0.85 | CA2 (0.53) | ALDH1A1HTTSMN1; SMN2PSMD10CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561585-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION, AND PREVENTION OF ECTOPIC CALCIFICATION | Sanifit Therapeutics S.A. (ES) | 2025-06-04 | — | — | EP | disclosed |
| EP-4562019-A1 | IP5 SUBSTITUTED COMPOUNDS | Sanifit Therapeutics S.A. (ES) | 2025-06-04 | — | — | EP | disclosed |
| US-20240109924-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | VIFOR (INTERNATIONAL) LTD. (CH) | 2024-04-04 | — | — | US | disclosed |
| WO-2024023359-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION, AND PREVENTION OF ECTOPIC CALCIFICATION | SANIFIT THERAPEUTICS, S.A. (ES) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024023360-A1 | IP5 SUBSTITUTED COMPOUNDS | SANIFIT THERAPEUTICS, S.A. (ES) | 2024-02-01 | — | — | WO | disclosed |
| EP-4284809-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | Sanifit Therapeutics S.A. (ES) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022162206-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | SANIFIT THERAPEUTICS, S.A. (ES) | 2022-08-04 | — | — | WO | disclosed |
| EP-4036097-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | Sanifit Therapeutics S.A. (ES) | 2022-08-03 | — | — | EP | disclosed |
| EP-0697407-B1 | Pyrimidinedione derivatives and antiarrhythmic compositions containing same | MITSUI TOATSU CHEMICALS (JP) | 1997-06-25 | — | — | EP | disclosed |
| EP-0697407-A1 | Pyrimidinedione derivatives and antiarrhythmic compositions containing same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109924-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | IPO4, TPX2, IPO9 | FKBP1A 2396/4885ALDH1A1 4700/4885BCHE 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.